308 related articles for article (PubMed ID: 20045715)
21. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
[TBL] [Abstract][Full Text] [Related]
22. Lysosomal cysteine proteases and antigen presentation.
Rudensky A; Beers C
Ernst Schering Res Found Workshop; 2006; (56):81-95. PubMed ID: 16329647
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human cathepsin H lacking the mini chain is an endopeptidase.
Vasiljeva O; Dolinar M; Turk V; Turk B
Biochemistry; 2003 Nov; 42(46):13522-8. PubMed ID: 14621998
[TBL] [Abstract][Full Text] [Related]
24. Substrate specificity of recombinant cysteine proteinase, CPB, of Leishmania mexicana.
Alves LC; Judice WA; St Hilaire PM; Meldal M; Sanderson SJ; Mottram JC; Coombs GH; Juliano L; Juliano MA
Mol Biochem Parasitol; 2001 Aug; 116(1):1-9. PubMed ID: 11463460
[TBL] [Abstract][Full Text] [Related]
25. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization.
Brömme D; Li Z; Barnes M; Mehler E
Biochemistry; 1999 Feb; 38(8):2377-85. PubMed ID: 10029531
[TBL] [Abstract][Full Text] [Related]
26. Cathepsins X and B can be differentiated through their respective mono- and dipeptidyl carboxypeptidase activities.
Therrien C; Lachance P; Sulea T; Purisima EO; Qi H; Ziomek E; Alvarez-Hernandez A; Roush WR; Ménard R
Biochemistry; 2001 Mar; 40(9):2702-11. PubMed ID: 11258881
[TBL] [Abstract][Full Text] [Related]
27. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands.
Honey K; Nakagawa T; Peters C; Rudensky A
J Exp Med; 2002 May; 195(10):1349-58. PubMed ID: 12021314
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin V, a novel and potent elastolytic activity expressed in activated macrophages.
Yasuda Y; Li Z; Greenbaum D; Bogyo M; Weber E; Brömme D
J Biol Chem; 2004 Aug; 279(35):36761-70. PubMed ID: 15192101
[TBL] [Abstract][Full Text] [Related]
29. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
Guncar G; Pungercic G; Klemencic I; Turk V; Turk D
EMBO J; 1999 Feb; 18(4):793-803. PubMed ID: 10022822
[TBL] [Abstract][Full Text] [Related]
31. Substrate specificity of recombinant osteoclast-specific cathepsin K from rabbits.
Aibe K; Yazawa H; Abe K; Teramura K; Kumegawa M; Kawashima H; Honda K
Biol Pharm Bull; 1996 Aug; 19(8):1026-31. PubMed ID: 8874809
[TBL] [Abstract][Full Text] [Related]
32. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain.
Rückrich T; Brandenburg J; Cansier A; Müller M; Stevanović S; Schilling K; Wiederanders B; Beck A; Melms A; Reich M; Driessen C; Kalbacher H
Biol Chem; 2006; 387(10-11):1503-11. PubMed ID: 17081125
[TBL] [Abstract][Full Text] [Related]
33. Human cathepsin F. Molecular cloning, functional expression, tissue localization, and enzymatic characterization.
Wang B; Shi GP; Yao PM; Li Z; Chapman HA; Brömme D
J Biol Chem; 1998 Nov; 273(48):32000-8. PubMed ID: 9822672
[TBL] [Abstract][Full Text] [Related]
34. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
[TBL] [Abstract][Full Text] [Related]
35. Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue.
Zavasnik-Bergant V; Sekirnik A; Golouh R; Turk V; Kos J
Biol Chem; 2001 May; 382(5):799-804. PubMed ID: 11517933
[TBL] [Abstract][Full Text] [Related]
36. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.
Riese RJ; Wolf PR; Brömme D; Natkin LR; Villadangos JA; Ploegh HL; Chapman HA
Immunity; 1996 Apr; 4(4):357-66. PubMed ID: 8612130
[TBL] [Abstract][Full Text] [Related]
37. Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme.
Araujo MC; Melo RL; Cesari MH; Juliano MA; Juliano L; Carmona AK
Biochemistry; 2000 Jul; 39(29):8519-25. PubMed ID: 10913258
[TBL] [Abstract][Full Text] [Related]
38. The slow-binding inhibition of cathepsin K by its propeptide.
Billington CJ; Mason P; Magny MC; Mort JS
Biochem Biophys Res Commun; 2000 Oct; 276(3):924-9. PubMed ID: 11027570
[TBL] [Abstract][Full Text] [Related]
39. Cathepsin K: a cysteine protease with unique kinin-degrading properties.
Godat E; Lecaille F; Desmazes C; Duchêne S; Weidauer E; Saftig P; Brömme D; Vandier C; Lalmanach G
Biochem J; 2004 Nov; 383(Pt. 3):501-6. PubMed ID: 15265002
[TBL] [Abstract][Full Text] [Related]
40. Reductive activation markedly increases the stability of cathepsins B and L to extracellular ionic conditions.
Dehrmann FM; Elliott E; Dennison C
Biol Chem Hoppe Seyler; 1996 Jun; 377(6):391-4. PubMed ID: 8839985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
